Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region

1996 • 5,154 citations

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

1997 • 4,490 citations

The BDNF val66met Polymorphism Affects Activity-Dependent Secretion of BDNF and Human Memory and Hippocampal Function

2003 • 3,746 citations

Allelic Variation of Human Serotonin Transporter Gene Expression

1996 • 2,225 citations

Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders

1996 • 1,780 citations

Synthesis of Serotonin by a Second Tryptophan Hydroxylase Isoform

2003 • 1,478 citations

The serotonin syndrome

1991 • 1,317 citations

A functional polymorphism in the monoamine oxidase A gene promoter

1998 • 1,070 citations

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

1997 • 995 citations

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

2001 • 818 citations

Summary of information on human CYP enzymes: human P450 metabolism data

2002 • 805 citations

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

2002 • 747 citations

Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

1999 • 722 citations

The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers

1998 • 679 citations

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.

1993 • 652 citations

Genes for schizophrenia? Recent findings and their pathophysiological implications

2003 • 610 citations

Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine

1998 • 605 citations

Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes

2002 • 559 citations

Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs

2002 • 551 citations

INCREASED SEROTONIN-2 BINDING SITES IN FRONTAL CORTEX OF SUICIDE VICTIMS

1983 • 527 citations

Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression

2003 • 494 citations

Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy

2002 • 434 citations

CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants: a first step towards subpopulation‐specific dosages

2001 • 429 citations

Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.

1999 • 427 citations

Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression

2000 • 410 citations

Association of antipsychotic druginduced weight gain with a 5-HT2C receptor gene polymorphism

2002 • 405 citations

Serotonin transporter gene polymorphism and antidepressant response

2000 • 392 citations

A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo

1999 • 372 citations

Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.

2000 • 350 citations

Genetic Polymorphism in the 5'-Flanking Region of HumanCYP1A2 Gene: Effect on the CYP1A2 Inducibility in Humans

1999 • 337 citations

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder

2002 • 334 citations

Association between clozapine response and allelic variation in 5-HT2A receptor gene

1995 • 330 citations

Interindividual Variability and Tissue-Specificity in the Expression of Cytochrome P450 3A mRNA

2002 • 315 citations

Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

1996 • 314 citations

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects

1993 • 311 citations

Clinical Pharmacokinetics of Mirtazapine

2000 • 307 citations

Common allelic variants of cytochrome P4503A4 and their prevalence in different populations

2002 • 306 citations

Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder

1997 • 305 citations

Metabolism of tricyclic antidepressants.

1999 • 285 citations

10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes*

1998 • 284 citations

Pharmacogenetics of Antidepressant Medication Intolerance

2003 • 284 citations

Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders

2002 • 251 citations

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6

2003 • 248 citations

Serotonin Subtype 2 Receptor Genes and Clinical Response to Clozapine in Schizophrenia Patients

1998 • 247 citations

Response and Remission Rates in Different Subpopulations With Major Depressive Disorder Administered Venlafaxine, Selective Serotonin Reuptake Inhibitors, or Placebo

2001 • 245 citations

Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients

1997 • 242 citations

Pharmacogenetics of Tardive Dyskinesia Combined Analysis of 780 Patients Supports Association with Dopamine D3 Receptor Gene Ser9Gly Polymorphism

2002 • 241 citations

Identification of a null allele of CYP2C9 in an African–American exhibiting toxicity to phenytoin

2001 • 237 citations

Extension of a Pilot Study: Impact From the Cytochrome P450 2D6 Polymorphism on Outcome and Costs Associated With Severe Mental Illness

2000 • 229 citations

Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients

2002 • 227 citations

Venlafaxine oxidation in vitro is catalysed by CYP2D6

1996 • 226 citations

Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-httlpr in delusional and nondelusional depression

2001 • 222 citations

The Effect of Paroxetine on 5-HT_2A Receptors in Depression: An [¹⁸F]Setoperone PET Imaging Study

2001 • 222 citations

Psychotropic Drugs, Cardiac Arrhythmia, and Sudden Death

2003 • 218 citations

Association study of a brain‐derived neurotrophic‐factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response

2003 • 216 citations

Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine

1998 • 214 citations

Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation Polymorphisms

1993 • 214 citations

The relationship between paroxetine and the sparteine oxidation polymorphism

1992 • 204 citations

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment

2002 • 201 citations

Polymorphism of the Promoter Region of the Serotonin 5-HT_2CReceptor Gene and Clozapine-Induced Weight Gain

2003 • 199 citations

Evidence for an association between a G-protein β3-gene variant with depression and response to antidepressant treatment

2000 • 198 citations

Initial conditions of serotonin transporter kinetics and genotype: influence on ssri treatment trial outcome

2002 • 195 citations

A novel mutant variant of the CYP2D6 gene (CYP2D617) common in a black African population: association with diminished debrisoquine hydroxylase activity

1996 • 193 citations

Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6

2000 • 189 citations

Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression

2001 • 188 citations

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

2003 • 187 citations

Association between clozapine response and allelic variation in the 5-HT2C receptor gene

1995 • 185 citations

Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment

2003 • 181 citations

Allelic, genotypic and phenotypic distributions of S-mephenytoin 4???-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world

1999 • 178 citations

Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism

2003 • 175 citations

Brain Derived Neurotrophic Factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia

2000 • 175 citations

Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.

1999 • 175 citations

Polymorphisms in dopamine receptors: what do they tell us?

2000 • 174 citations

Metabolism of the Newer Antidepressants

1998 • 174 citations

Role of the Smoking-Induced Cytochrome P450 (CYP)1A2 and Polymorphic CYP2D6 in Steady-State Concentration of Olanzapine

2003 • 173 citations

E- and Z-10-hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation

1981 • 171 citations

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia

2000 • 169 citations

Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics

2002 • 168 citations

Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in luman beings

1989 • 167 citations

Influence of a Functional Polymorphism Within the Promoter of the Serotonin Transporter Gene on the Effects of Total Sleep Deprivation in Bipolar Depression

1999 • 167 citations

Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity

2001 • 166 citations

D2 dopamine receptor polymorphism and brain regional glucose metabolism

1997 • 164 citations

Association of the MscI Polymorphism of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in Schizophrenia

1999 • 163 citations

Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype

1991 • 162 citations

Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.

2003 • 160 citations

The Role of Serotonin Transporter Protein Gene in Antidepressant-Induced Mania in Bipolar Disorder

2001 • 159 citations

Five Distinct Human Cytochromes Mediate Amitriptyline N‐Demethylation In Vitro: Dominance of CYP 2C19 and 3A4

1998 • 156 citations

The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry*

1996 • 156 citations

Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia

1999 • 153 citations

Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia

2001 • 152 citations

Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism

1992 • 150 citations

Untitled

2003 • 147 citations

Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism

1993 • 146 citations

Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia

1996 • 144 citations

Association Study of the Interleukin-1beta (C-511T) Genetic Polymorphism with Major Depressive Disorder, Associated Symptomatology, and Antidepressant Response

2003 • 144 citations

Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19

2001 • 143 citations

Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor

1997 • 140 citations

An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients

2003 • 140 citations

The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine

1991 • 139 citations

Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2C ser and DRD3 gly alleles to susceptibility

2000 • 139 citations

Manganese Superoxide Dismutase Gene Polymorphism and Schizophrenia Relation to Tardive Dyskinesia

2000 • 137 citations

Venlafaxine Serum Levels and CYP2D6 Genotype

2000 • 135 citations

Polymorphic debrisoquin hydroxylation in 757 Swedish subjects

1988 • 135 citations

Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine

1996 • 132 citations

CYP2D6 Inhibition by Fluoxetine, Paroxetine, Sertraline, and Venlafaxine in a Crossover Study: Intraindividual Variability and Plasma Concentration Correlations

2000 • 128 citations

Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)

1999 • 127 citations

Serotonin-6 receptor variant (C267T) and clinical response to clozapine

1999 • 126 citations

Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers

1997 • 126 citations

Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine

1996 • 125 citations

Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients

1999 • 121 citations

Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor

1997 • 119 citations

Human dopamine D4 receptor gene: frequent occurrence of a null allele and observation of homozygosity

1994 • 117 citations

Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity*

1996 • 116 citations

Tryptophan hydroxylase gene associated with paroxetine antidepressant activity

2001 • 115 citations

D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine

2003 • 114 citations

Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine

1994 • 113 citations

Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man

1980 • 111 citations

PCR-based genotyping for duplicated and deleted CYP2D6 genes

1996 • 110 citations

The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response

1998 • 109 citations

Serum Concentrations and Side Effects in Psychiatric Patients During Risperidone Therapy

1998 • 109 citations

The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin*

1996 • 109 citations

No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population

1999 • 104 citations

Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study

1997 • 104 citations

Disposition of clozapine in man: lack of association with debrisoquine and S‐mephenytoin hydroxylation polymorphisms.

1994 • 103 citations

The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol*

1996 • 102 citations

Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype

1986 • 101 citations

The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine

1999 • 101 citations

Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?

2001 • 100 citations

Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity

2002 • 100 citations

Lack of association between schizophrenia and alleles in the dopamine D₃ receptor gene

1993 • 100 citations

Haloperidol Disposition Is Dependent on the Debrisoquine Hydroxylation Phenotype

1992 • 99 citations

Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study*

1995 • 98 citations

Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism

1986 • 98 citations

CYP2D6 Inhibition by Fluoxetine, Paroxetine, Sertraline, and Venlafaxine in a Crossover Study: Intraindividual Variability and Plasma Concentration Correlations

2000 • 98 citations

Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia

1997 • 98 citations

Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients

1997 • 97 citations

Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype

1997 • 96 citations

CYP2D6 Status of Extensive Metabolizers After Multiple-Dose Fluoxetine, Fluvoxamine, Paroxetine, or Sertraline

1999 • 96 citations

Polymorphic Drug Metabolism in Schizophrenic Patients With Tardive Dyskinesia

1995 • 96 citations

Treatment-Resistance to Clozapine in Association With Ultrarapid CYP1A2 Activity and the C → A Polymorphism in Intron 1 of the CYP1A2 Gene: Effect of Grapefruit Juice and Low-Dose Fluvoxamine

2001 • 96 citations

Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response

2000 • 95 citations

New approaches to managing difficult-to-treat depressions.

2003 • 94 citations

Association between the methylenetetrahydrofolate reductase 677C→T missense mutation and schizophrenia

2000 • 93 citations

Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers

1999 • 93 citations

Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans.

2003 • 93 citations

Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder

2002 • 92 citations

Efficacy and Side-Effects of Clozapine: Testing for Association with Allelic Variation in the Dopamine D4 Receptor Gene

1996 • 92 citations

Single-dose kinetics of clomipramine: Relationship to the sparteine and S-mephenytoin oxidation polymorphisms

1994 • 92 citations

Relationship between adverse effects of antipsychotic treatment and dopamine D2 receptor polymorphisms in patients with schizophrenia

2002 • 92 citations

Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia

2001 • 90 citations

High and variable frequencies of CYP2C19 mutations

1999 • 90 citations

Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor

2001 • 90 citations

SSRIs antidepressant activity is influenced by Gβ3 variants

2003 • 90 citations

A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine

2002 • 88 citations

C677T polymorphism in methylenetetrahydrofolate reductase gene and psychoses

1998 • 87 citations

Low daily 10‐mg and 20‐mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)

2002 • 87 citations

Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine

2000 • 86 citations

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.

2001 • 86 citations

Lack of association between the T→C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia

2001 • 86 citations

Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia

2001 • 85 citations

Serotonin transporter promoter polymorphism is associated with attenuated prolactin response to fenfluramine

2001 • 85 citations

Association of theTaqI A Polymorphism of the Dopamine D₂Receptor Gene With Predisposition to Neuroleptic Malignant Syndrome

2001 • 84 citations

Association between the Ser9Gly Polymorphism of the Dopamine D3 Receptor Gene and Tardive Dyskinesia in Chinese Schizophrenic Patients

2001 • 84 citations

Functional polymorphism of −141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia

1998 • 84 citations

Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: A generalization of Steen's study onDRD3 and tardive dyskinesia

2000 • 83 citations

Amitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers

1986 • 82 citations

Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes

1984 • 82 citations

Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes*

1998 • 81 citations

Polymorphisms of the dopamine D 4 receptor and response to antipsychotic drugs

1999 • 81 citations

Clozapine response and the 5HT2C Cys23Ser polymorphism

1996 • 80 citations

The effects of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain

1996 • 80 citations

CYP2D6 Inhibition by Selective Serotonin Reuptake Inhibitors: Analysis of Achievable Steady‐State Plasma Concentrations and the Effect of Ultrarapid Metabolism at CYP2D6

2002 • 79 citations

Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia

2000 • 78 citations

Combined action of the ACE D- and the G-protein β3 T-allele in major depression: a possible link to cardiovascular disease?

2002 • 77 citations

Association between -1438G/A Promoter Polymorphism in the 5-HT<sub>2A</sub> Receptor Gene and Fluvoxamine Response in Japanese Patients with Major Depressive Disorder

2002 • 77 citations

In Vitro and In Vivo Studies on the Disposition of Mirtazapine in Humans

1997 • 76 citations

Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case–control study

2002 • 75 citations

Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients

2001 • 75 citations

Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects

1997 • 75 citations

Biotransformation of Post-Clozapine Antipsychotics

2000 • 74 citations

Involvement of CYP2D6 activity in the N-oxidation of procainamide in man

1999 • 74 citations

Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response11The experiments in this study were performed at the Molecular Biology Laboratory, Department of Psychiatry, Veterans General Hospital Taipei, Taipei, Taiwan.

2000 • 73 citations

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients

2000 • 72 citations

Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to theCYP2D6 genotype

1996 • 72 citations

Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal bartter syndrome: Therapeutic use of the cyclooxygenase-2 inhibitor nimesulide

2001 • 71 citations

The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism

2002 • 71 citations

Effects of the allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia

1999 • 70 citations

Amitriptyline metabolism: Relationship to polymorphic debrisoquine hydroxylation

1983 • 70 citations

Genetic variants of the serotonin system and weight change during clozapine treatment

2001 • 69 citations

Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients

1997 • 69 citations

Effectiveness of antidepressants: comparative remission rates.

2003 • 68 citations

Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response

2002 • 68 citations

Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response

1998 • 68 citations

No linkage or linkage disequilibrium between brain-derived neurotrophic factor (BDNF) dinucleotide repeat polymorphism and schizophrenia in Irish families

1998 • 68 citations

Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants

1999 • 67 citations

No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response

2000 • 67 citations

Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms

1997 • 66 citations

Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism

1996 • 65 citations

Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans

1991 • 65 citations

Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia

2001 • 65 citations

Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients

1995 • 65 citations

Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers.

1996 • 65 citations

Dopamine D3 receptor variant and tardive dyskinesia

2000 • 65 citations

Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia

2002 • 64 citations

Amitriptyline Pharmacokinetics and Clinical Response: II. Metabolic Polymorphism Assessed by Hydroxylation of Debrisoquine and Mephenytoin

1986 • 63 citations

Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia

2001 • 63 citations

Interaction of the ACE D Allele and the GNB3 825T Allele in Myocardial Infarction

2000 • 62 citations

Dopamine D3 receptor (DRD3) gene polymorphism is associated with the intensity of eye movement disturbances in schizophrenic patients and healthy subjects

2001 • 62 citations

Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome

2002 • 62 citations

Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype

2002 • 62 citations

The Impact of CYP2C19 and CYP2D6 Genotypes on Metabolism of Amitriptyline in Japanese Psychiatric Patients

2002 • 61 citations

Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man

1982 • 61 citations

Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia.

1995 • 60 citations

Steady-State Plasma Levels of Nortriptyline and Its Hydroxylated Metabolites in Japanese Patients: Impact of CYP2D6 Genotype on the Hydroxylation of Nortriptyline

2000 • 60 citations

Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients

2001 • 60 citations

Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.

2002 • 59 citations

Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia

2001 • 59 citations

Concentrations of the Enantiomers of Fluoxetine and Norfluoxetine After Multiple Doses of Fluoxetine in Cytochrome P4502D6 Poor and Extensive Metabolizers

2001 • 59 citations

Association analysis of polymorphism in the promoter region of the α2a-adrenoceptor gene with schizophrenia and clozapine response

2001 • 59 citations

Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin*

1996 • 58 citations

Substantial rise in sparteine metabolic ratio during haloperidol treatment.

1989 • 58 citations

Association Study of the 5-HT<sub>6</sub> Receptor Polymorphism (C267T) and Symptomatology and Antidepressant Response in Major Depressive Disorders

2001 • 57 citations

5-HT2 receptor gene locus: association with schizophrenia or treatment response not detected.

1996 • 57 citations

Effects of Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on Trimipramine Pharmacokinetics

2003 • 57 citations

Eye movement disturbances in schizophrenia and a polymorphism of catechol-O-methyltransferase gene

2002 • 56 citations

High and variable frequencies of CYP2C19 mutations

1999 • 55 citations

Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes

1999 • 55 citations

Lower Plasma Levels of Haloperidol in Smoking Than in Nonsmoking Schizophrenic Patients

1999 • 55 citations

Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia

2003 • 54 citations

Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism

1994 • 54 citations

Beta‐1‐adrenergic receptor gene in major depression: Influence on antidepressant treatment response

2003 • 54 citations

No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment

2002 • 53 citations

Evidence for an Association between the Dopamine D3 Receptor Gene DRD3 and Schizophrenia

1997 • 53 citations

Association study of Angiotensin I-converting enzyme polymorphism and symptomatology and antidepressant response in major depressive disorders

2002 • 53 citations

No association between dopamine D2 and D4 receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors

2001 • 53 citations

Association Analysis for Neuronal Nitric Oxide Synthase Gene Polymorphism with Major Depression and Fluoxetine Response

2003 • 53 citations

Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment

2002 • 52 citations

Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype

2003 • 52 citations

Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors

1997 • 52 citations

Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response

2002 • 52 citations

Catechol-O-methyltransferase and Monoamine Oxidase A Genotypes and Drug Response to Conventional Neuroleptics in Schizophrenia

2003 • 51 citations

Steady-state plasma levels of clomipramine and its metabolites: Impact of the sparteine/debrisoquine oxidation polymorphism

1992 • 51 citations

Hydroxylation of desmethylimipramine: Dependence on the debrisoquin hydroxylation phenotype

1987 • 50 citations

Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects

1992 • 50 citations

Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators

1987 • 50 citations

Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

2001 • 50 citations

Non‐linear fluvoxamine disposition

1998 • 50 citations

5-HT2 receptor gene locus

1996 • 50 citations

The Multifactorial Presentation of Depression in Acute Care

2013 • 49 citations

Angiotensin converting enzyme gene insertion/deletion polymorphism: Case‐control association studies in schizophrenia, major affective disorder, and tardive dyskinesia and a family‐based association study in schizophrenia

2002 • 49 citations

Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics

2002 • 49 citations

Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects

2001 • 47 citations

Chirality and drugs used in psychiatry: nice to know or need to know?

1999 • 47 citations

Steady State Plasma Levels of the Enantiomers of Trimipramine and of Its Metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-Phenotyped Patients

2000 • 46 citations

Effects of CYP2D6 Genotypes on Plasma Concentrations of Risperidone and Enantiomers of 9‐Hydroxyrisperidone in Japanese Patients with Schizophrenia

2003 • 46 citations

Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients

2000 • 45 citations

The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects

2002 • 44 citations

Steady-State Plasma Concentrations of Imipramine and Desipramine in Relation to S-Mephenytoin 4'-Hydroxylation Status in Japanese Depressive Patients

1996 • 43 citations

Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin

2000 • 43 citations

Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6

1993 • 42 citations

Effects of genetic defects in the CYP2C19 gene on the N‐demethylation of imipramine, and clinical outcome of imipramine therapy

1997 • 42 citations

Bupropion Plasma Levels and CYP2D6 Phenotype

1996 • 42 citations

The CYP2D6 Genotype and Plasma Concentrations of Mianserin Enantiomers in Relation to Therapeutic Response to Mianserin in Depressed Japanese Patients

1997 • 41 citations

Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan

1996 • 41 citations

A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone

1995 • 41 citations

The Effect of CYP2C19 and CYP2D6 Genotypes on the Metabolism of Clomipramine in Japanese Psychiatric Patients

2001 • 40 citations

Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position −2964 in the 5′-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia

2002 • 40 citations

Maprotiline metabolism appears to co‐segregate with the genetically‐ determined CYP2D6 polymorphic hydroxylation of debrisoquine.

1994 • 40 citations

Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes

2001 • 40 citations

Interactive effect of cytochrome P450 17α-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia

2002 • 38 citations

Clomipramine dose-effect study in patients with depression: Clinical end points and pharmacokinetics

1999 • 38 citations

Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m -chlorophenylpiperazine

1997 • 35 citations

Pathogenetic role of cyclooxygenase‐2 in hyperprostaglandin E syndrome/antenatal bartter syndrome: Therapeutic use of the cyclooxygenase‐2 inhibitor nimesulide

2001 • 35 citations

A Polymorphism of the Norepinephrine Transporter Gene in Bipolar Disorder and Schizophrenia: Lack of Association

2002 • 34 citations

Influence of Cyp2D6 Genetic Polymorphism on Ratios of Steady-state Serum Concentration to Dose of the Neuroleptic Zuclopenthixol

1996 • 33 citations

Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients

1997 • 33 citations

The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: A preliminary study in a psychiatric population

1999 • 33 citations

Melperone is an Inhibitor of the CYP2D6 Catalyzed O-demethylation of Venlafaxine

2003 • 29 citations

Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity

2003 • 29 citations

Genetic association analysis of 5-HT6 receptor gene polymorphism (267C/T) with tardive dyskinesia

2002 • 29 citations

Metabolism of Desipramine in Japanese Psychiatric Patients: The Impact of CYP2D6 Genotype on the Hydroxylation of Desipramine

2000 • 28 citations

Tardive dyskinesia is not associated with the serotonin gene polymorphism (5-HTTLPR) in Chinese

2000 • 28 citations

Association Study of the Estrogen Receptor Polymorphisms with Tardive Dyskinesia in Schizophrenia

2002 • 28 citations

Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6

2001 • 28 citations

Lack of association in Japanese patients between neuroleptic malignant syndrome and the TaqI A polymorphism of the dopamine D2 receptor gene

2003 • 27 citations

Lack of Association Between Neuroleptic Malignant Syndrome and Polymorphisms in the 5-HT_1Aand 5-HT_2AReceptor Genes

1998 • 27 citations

Enantiomeric antidepressant drugs should be considered on individual merit

2001 • 25 citations

Dopamine receptor D4 is not associated with antidepressant activity of sleep deprivation

1999 • 24 citations

Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan

1996 • 24 citations

Association Study of Apolipoprotein Eε4with Clinical Phenotype and Clozapine Response in Schizophrenia

2000 • 23 citations

The role of cytochrome P450 2D6 in the metabolism of moclobemide

1996 • 23 citations

Antidepressive Response to Sleep Deprivation in Unipolar Depression Is Not Associated with Dopamine D3 Receptor Genotype

2001 • 21 citations

Debrisoquine oxidation phenotype and neuroleptic‐induced dystonic reactions

1992 • 20 citations

New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update.

2002 • 20 citations

Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio

2003 • 20 citations

Steady State Concentrations of the Enantiomers of Mianserin and Desmethylmianserin in Poor and in Homozygous and Heterozygous Extensive Metabolizers of Debrisoquine

1998 • 20 citations

Association analysis of a polymorphism in the G‐protein stimulatory α subunit in patients with major depression*

2002 • 19 citations

Dopamine receptor polymorphisms and drug response in schizophrenia

2001 • 18 citations

Comparison of the pharmacokinetics of moclobemide in poor and efficient metabolizers of debrisoquine

1990 • 16 citations

N-methylation of maprotiline in debrisoquine/mephenitoin-phenotyped depressive patients

1985 • 15 citations

Possible inhibitory effect of diazepam on the metabolism of zotepine, an antipsychotic drug

1996 • 15 citations

Pharmacokinetics of Fluvoxamine in Relation to CYP2C19 Phenotype and Genotype

2002 • 13 citations

Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects.

1995 • 13 citations

Overview of antidepressant therapy.

2001 • 8 citations

Possible inhibitory effect of diazepam on the metabolism of zotepine, an antipsychotic drug

1996 • 4 citations